DOP2019000201A - Compuestos inhibidores del vih - Google Patents
Compuestos inhibidores del vihInfo
- Publication number
- DOP2019000201A DOP2019000201A DO2019000201A DO2019000201A DOP2019000201A DO P2019000201 A DOP2019000201 A DO P2019000201A DO 2019000201 A DO2019000201 A DO 2019000201A DO 2019000201 A DO2019000201 A DO 2019000201A DO P2019000201 A DOP2019000201 A DO P2019000201A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- formula
- inhibiting compounds
- hiv inhibiting
- compound
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La invención proporciona un compuesto de Fórmula I: o una sal farmacéuticamente aceptable del mismo como se describe en el presente documento. La invención también proporciona composiciones farmacéuticas que comprenden un compuesto de Fórmula I, procedimientos para preparar compuestos de Fórmula I, métodos terapéuticos para tratar la proliferación del virus del VIH, tratar el SIDA o retrasar la aparición de síntomas de SIDA en un mamífero usando compuestos de Fórmula I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762455348P | 2017-02-06 | 2017-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2019000201A true DOP2019000201A (es) | 2019-08-30 |
Family
ID=61244746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2019000201A DOP2019000201A (es) | 2017-02-06 | 2019-08-05 | Compuestos inhibidores del vih |
Country Status (34)
Country | Link |
---|---|
US (4) | US10294234B2 (es) |
EP (2) | EP3577110B1 (es) |
JP (4) | JP6814304B2 (es) |
KR (3) | KR102430812B1 (es) |
CN (3) | CN110536889B (es) |
AR (1) | AR110922A1 (es) |
AU (3) | AU2018215546B2 (es) |
BR (1) | BR102018002152A8 (es) |
CA (1) | CA3051588C (es) |
CL (1) | CL2019002204A1 (es) |
CO (1) | CO2019008531A2 (es) |
CR (1) | CR20190354A (es) |
CY (1) | CY1124276T1 (es) |
DK (1) | DK3577110T3 (es) |
DO (1) | DOP2019000201A (es) |
EA (1) | EA201991684A1 (es) |
ES (1) | ES2877595T3 (es) |
HR (1) | HRP20210732T1 (es) |
HU (1) | HUE054690T2 (es) |
IL (1) | IL268282B2 (es) |
JO (1) | JOP20180009A1 (es) |
LT (1) | LT3577110T (es) |
MX (2) | MX2019009212A (es) |
MY (1) | MY200608A (es) |
PE (1) | PE20191260A1 (es) |
PH (1) | PH12019501786A1 (es) |
PL (1) | PL3577110T3 (es) |
PT (1) | PT3577110T (es) |
SG (1) | SG11201907058TA (es) |
SI (1) | SI3577110T1 (es) |
TW (3) | TWI794629B (es) |
UA (1) | UA123298C2 (es) |
UY (1) | UY37592A (es) |
WO (1) | WO2018145021A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013006738A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
CR20190084A (es) | 2016-08-19 | 2019-05-02 | Gilead Sciences Inc | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih |
JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
AR112413A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
CN111836805B (zh) | 2018-02-15 | 2023-07-14 | 吉利德科学公司 | 吡啶衍生物及其用于治疗hiv感染的用途 |
CA3175557A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
CA3103522C (en) * | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
TWI829205B (zh) * | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
US11084832B2 (en) | 2019-03-22 | 2021-08-10 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
CN114727999A (zh) | 2019-11-26 | 2022-07-08 | 吉利德科学公司 | 用于预防hiv的衣壳抑制剂 |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
TW202237146A (zh) | 2021-01-25 | 2022-10-01 | 美商布里生物科學股份有限公司 | 使用腺苷衍生物及衣殼抑制劑之hiv組合療法 |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
TW202342448A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
TW202400165A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
CN115215803B (zh) * | 2022-09-19 | 2022-12-30 | 苏州美诺医药科技有限公司 | 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法 |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
DE2847064A1 (de) * | 1978-10-28 | 1980-05-08 | Boehringer Mannheim Gmbh | Verwendung von 2-cyanaziridinen als therapeutica bei strahlenschaeden |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5753652A (en) | 1991-07-03 | 1998-05-19 | Novartis Corporation | Antiretroviral hydrazine derivatives |
DK0521827T3 (da) | 1991-07-03 | 1996-11-11 | Ciba Geigy Ag | Farmakologisk virksomme hydrazinderivater og fremgangsmåde til deres fremstilling |
AU2003200066B9 (en) | 1992-03-11 | 2007-02-15 | Narhex Limited | Amine Derivatives of Oxo- and Hydroxy-substituted Hydrocarbons |
US5679688A (en) | 1992-03-11 | 1997-10-21 | Narhex Limited | Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons |
ES2093394T3 (es) | 1992-12-23 | 1996-12-16 | Ciba Geigy Ag | Derivados de hidrazina antiretrovirales. |
US5461067A (en) | 1993-02-25 | 1995-10-24 | Abbott Laboratories | Retroviral protease inhibiting compounds |
ES2177816T3 (es) | 1995-11-21 | 2002-12-16 | Novartis Ag | Derivados de azahexano como isosteros de sustrato de aspartato proteasas retroviricas. |
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
TW409125B (en) | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
AU2959397A (en) | 1996-05-31 | 1998-01-05 | Novartis Ag | Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues |
ATE213725T1 (de) | 1996-07-17 | 2002-03-15 | Novartis Ag | Anilinopeptid-derivate |
CH694251A5 (de) | 1999-07-14 | 2004-10-15 | Eprova Ag | Herstellung von Tetrahydropterin und Derivaten. |
EP2319824A3 (en) | 1999-12-23 | 2012-04-11 | Ampac Fine Chemicals LLC | Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)amine |
EP1392645A2 (en) | 2001-05-22 | 2004-03-03 | Elan Pharmaceuticals, Inc. | Aza hydroxylated ethyl amine compounds |
MXPA04001980A (es) | 2001-08-28 | 2005-02-17 | Pharmacia & Up John Company | Metodos de tratamiento de la enfermedad de alzheimer usando derivados de quinaldoil.amina de hidrocarburos substituidos con oxo e hidroxi. |
US7157489B2 (en) | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US20050131017A1 (en) * | 2003-12-11 | 2005-06-16 | Degoey David A. | HIV protease inhibiting compounds |
EP1697348B1 (en) | 2003-12-11 | 2011-12-28 | Abbott Laboratories | Hiv protease inhibiting compounds |
NZ590128A (en) | 2004-07-06 | 2012-08-31 | Abbott Lab | Prodrugs of HIV protease inhibitors |
SI2258376T1 (sl) | 2004-07-27 | 2019-04-30 | Gilead Sciences, Inc. | Analogi fosfonata spojin inhibitorjev HIV |
AP2007004079A0 (en) * | 2005-02-10 | 2007-08-31 | Medivir Ab | Hiv protease inhibitors |
CN101309911A (zh) | 2005-06-22 | 2008-11-19 | 麻萨诸塞州大学 | Hiv-1蛋白酶抑制剂及其制备方法和使用方法 |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
CA2657821A1 (en) * | 2006-07-21 | 2008-01-24 | Gilead Sciences, Inc. | Aza-peptide protease inhibitors |
CA2657936C (en) * | 2006-07-21 | 2017-01-10 | Gilead Sciences, Inc. | Antiviral protease inhibitors |
WO2008111116A1 (ja) | 2007-03-09 | 2008-09-18 | Pioneer Corporation | Av複合編集装置、av処理装置およびプログラム |
EP2139883A4 (en) | 2007-03-23 | 2011-06-22 | Univ Massachusetts | INHIBITORS OF HIV-1 PROTEASE |
RS51226B (sr) | 2007-06-12 | 2010-12-31 | Concert Pharmaceuticals Inc. | Derivati azapeptida kao inhibitori hiv proteaze |
US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
US20090076097A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched atazanavir |
CN101918365B (zh) | 2007-11-16 | 2013-10-09 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
WO2009114151A1 (en) | 2008-03-12 | 2009-09-17 | Nektar Therapeutics | Oligomer-amino acid and olgomer-atazanavir conjugates |
WO2009136365A1 (en) | 2008-05-08 | 2009-11-12 | Ranbaxy Laboratories Limited | Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof |
TWI466735B (zh) | 2008-09-18 | 2015-01-01 | Gs Yuasa Int Ltd | 紫外線照射裝置 |
JP5600116B2 (ja) | 2008-12-09 | 2014-10-01 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体のモジュレーター |
US20120041019A1 (en) | 2008-12-17 | 2012-02-16 | Mutz Mitchell W | Protease inhibitors |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
EP2292589A1 (en) | 2009-09-02 | 2011-03-09 | IMTM GmbH | Novel multifunctional peptidase inhibitors, especially for medical use |
WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
BR112012033689A2 (pt) | 2010-07-02 | 2019-09-24 | Gilead Sciences Inc | derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais |
MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
EP2611295B1 (en) | 2010-09-02 | 2017-07-19 | Purdue Research Foundation | Fused tricyclic ether carbamates and their use |
WO2012092168A1 (en) | 2010-12-27 | 2012-07-05 | Purdue Research Foundation | Fused 6,5 bicyclic ring system p2 ligands, and methods for treating hiv |
WO2012092188A1 (en) | 2010-12-27 | 2012-07-05 | Ghosh Arun K | Hydrogen bond forming p1 ligands and methods for treating hiv |
US9024038B2 (en) | 2010-12-27 | 2015-05-05 | Purdue Research Foundation | Compunds and methods for treating HIV |
PE20141066A1 (es) | 2011-04-21 | 2014-09-05 | Gilead Sciences Inc | Compuestos de benzotiazol |
WO2012170792A1 (en) | 2011-06-10 | 2012-12-13 | Concert Pharmaceuticals, Inc. | Atazanavir metabolite derivatives |
WO2013006738A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
WO2013106781A1 (en) | 2012-01-12 | 2013-07-18 | Gan Daniel L | Eversible candle holder |
PT3070081T (pt) | 2012-04-20 | 2018-05-21 | Gilead Sciences Inc | Derivados do ácido benzotiazol-6-ilacético e sua utilização para tratar uma infeção por vih |
NZ718708A (en) | 2012-12-21 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US20140221378A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
US20160002159A1 (en) * | 2013-02-13 | 2016-01-07 | Neal ZONDLO | Perfluoro-tert-butyl hydroxyproline |
WO2015097667A2 (en) | 2013-12-23 | 2015-07-02 | Cellworks Group, Inc., | A composition, process of preparation of said composition, kit and a method of treating cancer |
WO2015175704A1 (en) * | 2014-05-14 | 2015-11-19 | The Regents Of The University Of California | Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria |
EP3142659B1 (en) | 2014-05-16 | 2021-03-24 | Purdue Research Foundation | Hiv-1 protease inhibitors and uses thereof |
EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
EP3515897B1 (en) | 2016-09-19 | 2021-08-18 | H. Lundbeck A/S | Piperazine carbamates as modulators of magl and/or abhd6 and their use |
JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
-
2017
- 2017-02-06 JO JOP/2018/0009A patent/JOP20180009A1/ar unknown
-
2018
- 2018-01-31 BR BR102018002152A patent/BR102018002152A8/pt active Search and Examination
- 2018-02-02 UY UY0001037592A patent/UY37592A/es not_active Application Discontinuation
- 2018-02-02 AR ARP180100247A patent/AR110922A1/es unknown
- 2018-02-05 TW TW109126112A patent/TWI794629B/zh active
- 2018-02-05 WO PCT/US2018/016893 patent/WO2018145021A1/en active Application Filing
- 2018-02-05 KR KR1020197025847A patent/KR102430812B1/ko active IP Right Grant
- 2018-02-05 LT LTEP18706072.8T patent/LT3577110T/lt unknown
- 2018-02-05 JP JP2019542392A patent/JP6814304B2/ja active Active
- 2018-02-05 PT PT187060728T patent/PT3577110T/pt unknown
- 2018-02-05 PE PE2019001536A patent/PE20191260A1/es unknown
- 2018-02-05 EP EP18706072.8A patent/EP3577110B1/en active Active
- 2018-02-05 SI SI201830292T patent/SI3577110T1/sl unknown
- 2018-02-05 EP EP21165835.6A patent/EP3909949A1/en active Pending
- 2018-02-05 CN CN201880023198.1A patent/CN110536889B/zh active Active
- 2018-02-05 PL PL18706072T patent/PL3577110T3/pl unknown
- 2018-02-05 EA EA201991684A patent/EA201991684A1/ru unknown
- 2018-02-05 KR KR1020237021040A patent/KR20230097222A/ko not_active Application Discontinuation
- 2018-02-05 CR CR20190354A patent/CR20190354A/es unknown
- 2018-02-05 HU HUE18706072A patent/HUE054690T2/hu unknown
- 2018-02-05 US US15/888,749 patent/US10294234B2/en active Active
- 2018-02-05 AU AU2018215546A patent/AU2018215546B2/en active Active
- 2018-02-05 DK DK18706072.8T patent/DK3577110T3/da active
- 2018-02-05 CN CN202210907879.2A patent/CN115093421A/zh active Pending
- 2018-02-05 MX MX2019009212A patent/MX2019009212A/es unknown
- 2018-02-05 UA UAA201909440A patent/UA123298C2/uk unknown
- 2018-02-05 MY MYPI2019004469A patent/MY200608A/en unknown
- 2018-02-05 TW TW107103968A patent/TWI701243B/zh active
- 2018-02-05 TW TW112103166A patent/TW202344506A/zh unknown
- 2018-02-05 CN CN202211475398.5A patent/CN115991708A/zh active Pending
- 2018-02-05 KR KR1020227027022A patent/KR102547909B1/ko active Application Filing
- 2018-02-05 CA CA3051588A patent/CA3051588C/en active Active
- 2018-02-05 SG SG11201907058TA patent/SG11201907058TA/en unknown
- 2018-02-05 ES ES18706072T patent/ES2877595T3/es active Active
-
2019
- 2019-03-26 US US16/364,487 patent/US10752636B2/en active Active
- 2019-07-25 IL IL268282A patent/IL268282B2/en unknown
- 2019-08-02 MX MX2022012616A patent/MX2022012616A/es unknown
- 2019-08-05 CO CO2019008531A patent/CO2019008531A2/es unknown
- 2019-08-05 DO DO2019000201A patent/DOP2019000201A/es unknown
- 2019-08-05 CL CL2019002204A patent/CL2019002204A1/es unknown
- 2019-08-05 PH PH12019501786A patent/PH12019501786A1/en unknown
-
2020
- 2020-03-02 US US16/805,933 patent/US11078208B1/en active Active
- 2020-11-04 AU AU2020264300A patent/AU2020264300B2/en active Active
- 2020-12-02 JP JP2020200176A patent/JP7105853B2/ja active Active
-
2021
- 2021-02-04 JP JP2021016635A patent/JP7282112B2/ja active Active
- 2021-04-07 US US17/224,557 patent/US20230027055A1/en active Pending
- 2021-05-11 HR HRP20210732TT patent/HRP20210732T1/hr unknown
- 2021-06-30 CY CY20211100584T patent/CY1124276T1/el unknown
-
2022
- 2022-09-05 JP JP2022140748A patent/JP2022172294A/ja active Pending
- 2022-11-19 AU AU2022271510A patent/AU2022271510A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000201A (es) | Compuestos inhibidores del vih | |
CO2020004301A2 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
AR118707A1 (es) | Inhibidores de la proteasa del vih | |
UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
ECSP17073878A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
CO2019004034A2 (es) | Compuesto de piridina | |
CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
CR20130043A (es) | Compuestos terapéuticos | |
CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CR20190446A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
PE20160180A1 (es) | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos. | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
EA202091169A1 (ru) | Применяемые в качестве ингибиторов iap миметики smac и их применение | |
CL2020000251A1 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico. | |
EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний |